Anaïs Schavgoulidze, Jill Corre, Mehmet K Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Hervé Avet-Loiseau
Multiple Myeloma (MM) is characterized by a huge heterogeneity at the molecular level. The RAS/RAF pathway is the most frequently mutated, in about 50% of the patients. However, these mutations are frequently subclonal, suggesting a secondary event. Since these genes are part of our routine next-generation sequencing (NGS) panel, we analyzed >10,000 patients with different plasma cell disorders in order to describe the RAS/RAF landscape. In this large cohort of patients, almost 61% of the patients presented a RAS/RAF mutation at diagnosis or relapse, but much lower frequencies in pre-symptomatic cases...
April 21, 2024: Blood